Download
s00228-021-03134-9.pdf 433,02KB
WeightNameValue
1000 Titel
  • A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues
1000 Autor/in
  1. Hasford, J. |
  2. Bruchmann, F. |
  3. Lutz, M. |
  4. Thürmann, P. |
  5. Schmiedl, Sven |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-06-18
1000 Erschienen in
1000 Quellenangabe
  • 77(11):1697-1704
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00228-021-03134-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212270/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!Reporting of adverse drug reactions (ADRs) by patients is essential for a comprehensive risk-benefit evaluation of drugs after marketing, but only few data are available regarding patient-centred web-based ADR reporting systems. Hence, we aimed to analyze ADRs reported by patients with a particular emphasis on novel drugs and serious ADRs not yet labelled in the respective summary of product characteristics (SPC).!##!Methods!#!All ADR reports received by a web-based, patient-centred platform ( www.nebenwirkungen.de ) between April 1, 2019, and September 1, 2020, were descriptively analyzed. ADRs and drugs were coded automatically according to MedDRA and ATC classification system. SPC labelling of reported ADRs for novel drugs marketed since 2015 was checked manually.!##!Results!#!In total, 13,515 patient reports including 29,529 ADRs were received during the study period (serious ADRs [SADRs] n = 1,318; 4.5%). Women were affected in more than two-thirds of ADR reports. The most common patient-reported ADRs were nausea, dizziness and headache, whereas arrhythmia, intestinal obstruction and erectile dysfunction were the most frequent SADRs. Ciprofloxacin, levothyroxine and venlafaxine were the compounds most frequently suspected for causing both ADRs and SADRs. Regarding novel compounds, 289 reports including 739 ADRs were received (mainly fatigue, headache and myalgia). Three hundred thirty-one (44.8%) out of those ADRs were not yet labelled in the respective SPC, whereof twelve were SADRs.!##!Conclusion!#!The majority of patient-reported ADRs were non-serious. However, a relevant number of non-labelled even serious ADRs was reported for novel compounds by patients. Despite well-known limitations of patient-reported ADRs, this web-based ADR reporting system contributes to the identification of new ADRs and thus can help to improve patients' safety complementing other pharmacovigilance instruments.
1000 Sacherschließung
lokal Adverse drug reaction
lokal Female [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Pharmacovigilance [MeSH]
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Drug safety
lokal SPC
lokal Middle Aged [MeSH]
lokal Non-labelled ADR
lokal Adverse Drug Reaction Reporting Systems/statistics
lokal Patients/statistics
lokal Male [MeSH]
lokal ADR reporting by patients
lokal Young Adult [MeSH]
lokal Adverse Drug Reaction Reporting Systems/organization
lokal Pharmacoepidemiology and Prescription
lokal Internet/statistics
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SGFzZm9yZCwgSi4=|https://frl.publisso.de/adhoc/uri/QnJ1Y2htYW5uLCBGLg==|https://frl.publisso.de/adhoc/uri/THV0eiwgTS4=|https://frl.publisso.de/adhoc/uri/VGjDvHJtYW5uLCBQLg==|https://orcid.org/0000-0003-4844-0112
1000 Hinweis
  • DeepGreen-ID: 157cbd9b778741cdb0d0bddc1df8ed65 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6451583.rdf
1000 Erstellt am 2023-05-11T14:03:41.471+0200
1000 Erstellt von 322
1000 beschreibt frl:6451583
1000 Zuletzt bearbeitet 2023-10-24T06:50:50.521+0200
1000 Objekt bearb. Tue Oct 24 06:50:50 CEST 2023
1000 Vgl. frl:6451583
1000 Oai Id
  1. oai:frl.publisso.de:frl:6451583 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source